Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.

被引：0
|
作者：
Patnaik, Amita
Socinski, Mark A.
Gubens, Matthew A.
Gandhi, Leena
Stevenson, James
Bachman, Robert D.
Bourque, Jennifer
Ge, Joy Yang
Im, Ellie
Gadgeel, Shirish M.
机构：
[1] START, San Antonio, TX USA
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] UC San Francisco, San Francisco, CA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8011
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A PHASE II STUDY OF DOCETAXEL MONOTHERAPY IN SECOND-LINE TREATMENT IN PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Reza, M. S.
    Hai, M. A.
    Chowdhury, Q.
    ANNALS OF ONCOLOGY, 2008, 19 : 119 - 120
  • [42] Survival data from EMPOWER-Lung 4: Phase II study of cemiplimab plus ipilimumab in the second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC)
    Shim, B. Y.
    Lee, S.
    de Castro Carpeno, J.
    Chiu, C-H.
    Cobo, M.
    Kim, H. R.
    Ryu, J. S.
    Majem Tarruella, M.
    Summers, Y.
    Thomas, C. A.
    Xu, Y.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S760 - S760
  • [43] Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Hanna, N. H.
    Estes, D.
    Arnott, J.
    Marcotte, S.
    Hannah, A.
    Sidor, C. F.
    West, H.
    Clamon, G.
    Hoang, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] Weekly docetaxel as second-line therapy in non-small cell lung cancer: a phase II study
    Rossi, D
    Graziano, F
    Ugolini, M
    Dennetta, D
    Alessandroni, P
    Catalano, V
    Giordani, P
    Fedeli, SL
    Fedeli, A
    Catalano, G
    TUMORI JOURNAL, 2004, 90 (01): : 50 - 53
  • [45] Second-line therapy and advanced non-small cell lung cancer: What about smoking?
    Braillon, Alain
    LUNG CANCER, 2018, 122 : 257 - 257
  • [46] Weekly docetaxel and vinorelbine as second-line therapy in advanced non-small cell lung cancer
    Huber, R
    Schmidt, M
    Borgmeier, A
    LUNG CANCER, 2005, 49 : S248 - S248
  • [47] Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study
    G. Robinet
    F. Barlesi
    P. Fournel
    H. Berard
    R. Corre
    A. Vergnenegre
    L. Falchero
    P-J. Souquet
    A. Tisseron-Carrasco
    C. Chouaid
    Targeted Oncology, 2007, 2 : 63 - 71
  • [48] Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study
    Robinet, G.
    Barlesi, F.
    Fournel, P.
    Berard, H.
    Corre, R.
    Vergnenegre, A.
    Falchero, L.
    Souquet, P-J.
    Tisseron-Carrasco, A.
    Chouaid, C.
    TARGETED ONCOLOGY, 2007, 2 (02) : 63 - 71
  • [49] Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
    Govindan, Ramaswamy
    Morgensztern, Daniel
    Kommor, Michael D.
    Herbst, Roy S.
    Schaefer, Paul
    Gandhi, Jitendra
    Saito, Kaku
    Zergebel, Christopher
    Schiller, Joan
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (04) : 790 - 795
  • [50] Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer
    Hoang, Tien
    Kim, KyungMann
    Merchant, Joseph
    Traynor, Anne M.
    McGovern, James
    Oettel, Kurt R.
    Sanchez, Fredrico A.
    Ahuja, Harish G.
    Hensing, Thomas A.
    Larson, Martha
    Schiller, Joan H.
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (03) : 218 - 225
12345